Designer natriuretic peptides (NPs) are novel hybrid peptides that are engineered from the native NPs through addition, deletion, or substitution of amino acid(s) with a goal toward optimization of pharmacological actions while minimizing undesirable effects. In this article, selected peptides that were designed in our laboratory are reviewed, and future directions for research and development of designer NPs are discussed.
WeiCM, KimCH, MillerVM, . Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993; 92:2048–2052.
2.
de BoldAJ, BorensteinHB, VeressAT, . A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 28:89–94.
3.
SudohT, KangawaK, MinaminoN, . A new natriuretic peptide in porcine brain. Nature. 1988; 332:78–81.
4.
SudohT, MinaminoN, KangawaK, . C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990; 168:863–870.
5.
Schulz-KnappeP, ForssmannK, HerbstF, . Isolation and structural analysis of “urodilatin,” a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr. 1988; 66:752–759.
6.
SchweitzH, VigneP, MoinierD, . A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992; 267:13928–13932.
LisyO, LainchburyJG, LeskinenH, . Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, Dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001; 37:1089–1094.
9.
BestPJ, BurnettJC, WilsonSH, . Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 2002; 55:375–384.
10.
KollerKJ, LoweD, BennettG, . Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991; 252:120–123.
11.
SugaS, NakaoK, HosodaK, . Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992; 130:229–239.
12.
SinghG, KucRE, MaguireJJ, . Novel snake venom ligand Dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res. 2006; 99:183–190.
WeiCM, KimCH, KhraibiAA, . Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension. 1994; 23:903–907.
15.
WoodardGE, LiX, BrownJ, . Receptor subtypes for vasonatrin peptide in renal glomeruli and arteries [published correction appears in Regul Pept 2008;2147(2001-2003):2110]. Regul Pept. 2005; 129:183–189.
16.
FengHS, ZhangZ, ZhuX, . Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide (translated from Chinese). Sheng Li Xue Bao. 1999; 51:515–520.
17.
YuJ, ZheX, WeiG, . Vasorelaxing role of vasonatrin peptide in human intramammary artery in vitro (translated from Chinese). Sheng Li Xue Bao. 2003; 55:187–190.
18.
LuSY, ZhuMZ, GuoHT, . Inhibition of moderate hypoxia-induced protein synthesis by vasonatrin peptide in cultured neonatal rat cardiomyocytes (translated from Chinese). Sheng Li Xue Bao. 2002; 54:7–11.
19.
DongMQ, ZhuMZ, YuJ, . Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats (translated from Chinese). Sheng Li Xue Bao. 2000; 52:252–254.
20.
LisyO, HuntleyBK, McCormickDJ, . Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008; 52:60–68.
21.
SuwaM, SeinoY, NomachiY, . Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005; 69:283–290.
22.
Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial [published correction appears in JAMA 2002;1288:1577]. JAMA. 2002; 287:1531–1540.
23.
MitrovicV, . Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006; 27:2823–2832.
24.
DornerGT, SelenkoN, KralT, . Hemodynamic effects of continuous urodilatin infusion: a dose-finding study. Clin Pharmacol Ther. 1998; 64:322–330.
25.
WeiCM, AarhusLL, MillerVM, . Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993; 264:H71–H73.
26.
BurnettJCJr., OpgenorthTJ, GrangerJP. The renal action of atrial natriuretic peptide during control of glomerular filtration. Kidney Int. 1986; 30:16–19.
27.
BurnettJCJr., KorinekJ. The tumultuous journey of nesiritide: past, present, and future. Circ Heart Fail. 2008; 1:6–8.
28.
SoekiT, KishimotoI, OkumuraH, . C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005; 45:608–616.
29.
ClavellAL, StingoAJ, WeiCM, . C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 1993; 264:R290–295.
30.
LisyO, BurnettJCJr.The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP [abstract]. J Am Coll Cardiol. 2003; 41:312A.
31.
LeeCY, BoerrigterG, HartyGJ, . Pharmacodynamic profile of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide [abstract]. Circulation. 2007; 116(suppl II):II–550.
32.
LisyO, HuntleyBK, McCormickDJ, . Design, synthesis and unique biological actions of CD-NP: a novel CNP-like chimeric natriuretic peptide [abstract]. Circulation. 2006; 114:II–440.
33.
LeeCY, SandbergSM, ChenHH, . Renal cyclic GMP stimulating actions of a novel chimeric natriuretic peptide CD-NP in isolated glomeruli: evidence for NPR-A activation [abstract]. J Card Fail. 2008; 14:S11.
34.
HuntleyBK, BurnettJJC. Anti-proliferative mechanisms of BNP in cultured human cardiac fibroblasts: role for the clearance receptor, p21 and cyclin D1 [abstract]. J Card Fail. 2006; 12:S43.
35.
LeeCYW, ChenH, LieuH, . A phase I clinical trial on a novel chimeric natriuretic peptide, CD-NP [abstract]. J Am Coll Cardiol. 2008; 51:A324.
36.
LettsG, LoscalzoJ. Frontiers in nephrology: targeting inflammation using novel nitric oxide donors. J Am Soc Nephrol. 2007; 18:2863–2869.
37.
MillsRM, LeJemtelT, HortonD, . Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 1999; 34:155–162.
38.
KitakazeM, AsakuraM, KimJ, . Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370:1483–1493.
KasamaS, FuruyaM, ToyamaT, . Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2007; 49:667–674.
41.
ChenH, SchirgerJ, LermanA, . Intravenous BNP at the time of acute anterior myocardial infarction in humans improves left ventricular remodeling [abstract]. Circulation. 2005.
42.
ParkK, ItohH, YamaharaK, . Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology. 2008; 149:483–491.
43.
ChenHH, RedfieldMM, NordstromLJ, . Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004; 10:115–119.
44.
CataliottiA, ShirgerJ, MartinF, . Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005; 112:836–840.
45.
CataliottiA, JamesK, ChenHH, . Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008; 118:1729–1736.
46.
SengenesC, BerlanM, DeGlisezinski I, . Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000; 14:1345–1351.
47.
MeirhaegheA, SanduM, McCarthyM, . Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet. 2007; 16:1343–1350.
48.
VeselyBA, McAfeeQ, GowerWRJr., . Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest. 2003; 33:998–1005.
